Literature DB >> 8823690

Risk factors for Pneumocystis carinii pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus.

A Kadoya1, J Okada, Y Iikuni, H Kondo.   

Abstract

OBJECTIVE: To investigate risk factors for Pneumocystis carinii pneumonia (PCP) in patients with systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis (PM/DM).
METHODS: The subjects were 75 patients hospitalized because of SLE or PM/DM who were administered corticosteroids 40 mg/day or above as prednisolone. The relationship between clinical symptoms of SLE and PM/DM and the occurrence of PCP was evaluated.
RESULTS: Seven patients (9.3%) developed PCP and 3 died. Interstitial pulmonary fibrosis was observed in all 7 patients who developed PCP, and its incidence was significantly higher (p < 0.001) than in those who did not develop PCP (6/68). The incidence of PCP in patients with SLE was 1.7%, but that of patients with PM/DM was 37.5%. The peripheral blood lymphocyte count was 1052.7/microliters in patients who developed PCP, which was significantly lower (p < 0.01) than 1841.6/microliters in patients who did not develop PCP.
CONCLUSION: A low peripheral lymphocyte count and interstitial pulmonary fibrosis were considered risk factors for PCP in patients administered corticosteroids for SLE or PM/DM.

Entities:  

Mesh:

Year:  1996        PMID: 8823690

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  22 in total

1.  Interstitial Lung Disease in Idiopathic Inflammatory Myopathy.

Authors:  Lesley Ann Saketkoo; Dana P Ascherman; Vincent Cottin; Lisa Christopher-Stine; Sonye K Danoff; Chester V Oddis
Journal:  Curr Rheumatol Rev       Date:  2010-05

Review 2.  Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review.

Authors:  Matthew E Falagas; Katerina G Manta; Gregoria I Betsi; Georgios Pappas
Journal:  Clin Rheumatol       Date:  2006-12-21       Impact factor: 2.980

3.  Pneumocystis jirovecii pneumonia prophylaxis in a 42-year-old woman on immunosuppressive therapy.

Authors:  Sheliza Halani; Nisha Andany; Rupal Shah
Journal:  CMAJ       Date:  2020-10-26       Impact factor: 8.262

Review 4.  Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?

Authors:  Rachel M Wolfe; James E Peacock
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

Review 5.  Interstitial lung disease in polymyositis and dermatomyositis.

Authors:  Armin Schnabel; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 6.  Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients.

Authors:  Martin Rodriguez; Jay A Fishman
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Red fist and muscle weakness with a rare complication.

Authors:  Iris van Groeningen; Joyce Arnoldus; Roos Perenboom; Alexandre Voskuyl
Journal:  BMJ Case Rep       Date:  2014-02-20

8.  Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus.

Authors:  Ratchaya Lertnawapan; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2008-09-25       Impact factor: 2.631

9.  Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.

Authors:  Gabriela Schmajuk; Kashif Jafri; Michael Evans; Stephen Shiboski; Milena Gianfrancesco; Zara Izadi; Sarah L Patterson; Ishita Aggarwal; Urmimala Sarkar; R Adams Dudley; Jinoos Yazdany
Journal:  Semin Arthritis Rheum       Date:  2018-11-03       Impact factor: 5.532

Review 10.  [Screening investigations during intensified immunosuppression in children and adolescents. Part 1].

Authors:  F Speth; N Wellinghausen; J-P Haas
Journal:  Z Rheumatol       Date:  2013-10       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.